BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock Price, Quote, News and Overview
NASDAQ:DRUG - Nasdaq - CA10919W4056 - Common Stock - Currency: USD
DRUG Quote, Performance and Key Statistics
NASDAQ:DRUG (3/7/2025, 8:20:20 PM)
34.5
-1.4 (-3.9%)
The current stock price of DRUG is 34.5 USD. In the past month the price decreased by -15.48%. In the past year, price increased by 2111.54%.
DRUG Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About DRUG
Company Profile
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-02-08. The firm is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.
Company Info
BRIGHT MINDS BIOSCIENCES INC
19 Vestry Street
New York City NEW YORK US
Employees: 0
Company Website: https://brightmindsbio.com/
Investor Relations: http://brightmindsbio.com/investors/
Phone: 16478658622
BRIGHT MINDS BIOSCIENCES INC / DRUG FAQ
What is the stock price of BRIGHT MINDS BIOSCIENCES INC today?
The current stock price of DRUG is 34.5 USD. The price decreased by -3.9% in the last trading session.
What is the ticker symbol for BRIGHT MINDS BIOSCIENCES INC stock?
The exchange symbol of BRIGHT MINDS BIOSCIENCES INC is DRUG and it is listed on the Nasdaq exchange.
On which exchange is DRUG stock listed?
DRUG stock is listed on the Nasdaq exchange.
What is BRIGHT MINDS BIOSCIENCES INC worth?
BRIGHT MINDS BIOSCIENCES INC (DRUG) has a market capitalization of 242.88M USD. This makes DRUG a Micro Cap stock.
How many employees does BRIGHT MINDS BIOSCIENCES INC have?
BRIGHT MINDS BIOSCIENCES INC (DRUG) currently has 0 employees.
What are the support and resistance levels for BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?
BRIGHT MINDS BIOSCIENCES INC (DRUG) has a support level at 33.18 and a resistance level at 37.19. Check the full technical report for a detailed analysis of DRUG support and resistance levels.
Should I buy BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DRUG, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DRUG, evaluating the profitability, health, valuation and growth aspects
- BRIGHT MINDS BIOSCIENCES INC (DRUG) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRIGHT MINDS BIOSCIENCES INC (DRUG) Sales and EPS estimates to see what analysts future expectations are.
- BRIGHT MINDS BIOSCIENCES INC (DRUG) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRIGHT MINDS BIOSCIENCES INC (DRUG) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock Chart to make your own analysis
- BRIGHT MINDS BIOSCIENCES INC (DRUG) Latest news and press-releases to stay up to date.
Does BRIGHT MINDS BIOSCIENCES INC (DRUG) stock pay dividends?
DRUG does not pay a dividend.
What is the Price/Earnings (PE) ratio of BRIGHT MINDS BIOSCIENCES INC (DRUG)?
BRIGHT MINDS BIOSCIENCES INC (DRUG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
What is the Short Interest ratio of BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?
The outstanding short interest for BRIGHT MINDS BIOSCIENCES INC (DRUG) is 2.66% of its float. Check the ownership tab for more information on the DRUG short interest.
DRUG Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to DRUG. When comparing the yearly performance of all stocks, DRUG is one of the better performing stocks in the market, outperforming 99.99% of all stocks.
DRUG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRUG. While DRUG seems to be doing ok healthwise, there are quite some concerns on its profitability.
DRUG Financial Highlights
Over the last trailing twelve months DRUG reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 86.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.83% | ||
| ROE | -1.85% | ||
| Debt/Equity | 0 |
DRUG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to DRUG. The Buy consensus is the average rating of analysts ratings from 7 analysts.